Radiochemotherapy with amifostine cytoprotection for head and neck cancer
| Autor: | Jens Büntzel, Julius Schuth, Klaus Küttner, Michael Glatzel |
|---|---|
| Rok vydání: | 1998 |
| Předmět: |
Adult
Male medicine.medical_specialty medicine.medical_treatment Antineoplastic Agents Radiation-Protective Agents Gastroenterology law.invention Carboplatin chemistry.chemical_compound Amifostine Randomized controlled trial law Internal medicine Mucositis Medicine Humans Aged business.industry Incidence (epidemiology) Head and neck cancer Middle Aged medicine.disease Combined Modality Therapy Surgery Radiation therapy Treatment Outcome Oncology chemistry Head and Neck Neoplasms Female business Chemoradiotherapy medicine.drug |
| Zdroj: | Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer. 6(2) |
| ISSN: | 0941-4355 |
| Popis: | A randomized study was conducted to evaluate the protective activity of amifostine (A) against the dose-limiting toxicities of radiochemotherapy (RCT). Patients with head and neck cancer received radiotherapy (2 Gy/day 5 days a week up to 60 Gy) with carboplatin 70 mg/m2 on days 1-5 and 21-25 inclusive. Patients either received RCT alone (n = 14) or RCT + A at a dose of 500 mg prior to treatment with carboplatin (n = 25). There was a significant reduction in the incidence of grade 3/4 mucositis (P0.0001), acute grade 2 xerostomia (P0.0001) and grade 3/4 thrombocytopenia (P = 0.012) in these patients who received A. The incidence of grade 2 late xerostomia at 12 months is 16.7% and the incidence of loss of taste is 0% in patients treated with A, as opposed to 54.5% and 63.6% in patients who received RCT alone. There were 18 (72%) complete responses (CR) and 6 (24%) partial responses (PR) in patients who received A, compared with 6 (43%) CR and 6 PR (43%) in patients treated with RCT alone. The disease-free survival at 12 months is 85.7% in the RCT + A arm and 78.6% in the RCT alone arm. The use of amifostine reduces the incidence and severity of acute and late toxicities associated with RCT whilst preserving antitumour activity. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink